MAIA Biotechnology presented highlights from two poster presentations at SITC 2025, focusing on Phase 2 and Phase 3 clinical trials of ateganosine for NSCLC treatment.
The company confirmed 12 patients enrolled in Phase 2 THIO-101 to date and expansion trials in new countries.
Posters for the ongoing trials were made available on MAIA's website and the SEC's site.
Fast Track Designation
FDA granted Fast Track designation for ateganosine for NSCLC treatment.
Patient Progress
12 patients enrolled in Phase 2 THIO-101; Phase 3 trial screening started.
Potential Approval
Based on positive results, early commercial approval from the FDA is anticipated.
- MAIA's ateganosine shows promising results in advanced NSCLC patients, with a survival rate of 17.8 months observed so far.
- The sequential treatment of ateganosine followed by PD-(L)1 inhibitors demonstrates profound and persistent tumor responses.
MAIA Biotechnology's ateganosine continues to show potential as a novel NSCLC treatment with positive clinical trial outcomes. The company is optimistic about the future commercial approval and impact on patients with unmet medical needs.